Mann mit Wirtschaftszeitung (Symbolbild).
Quelle: - pixabay.com:
Google
PR Newswire  | 

GRAIL to Announce Third Quarter 2025 Financial Results

PR Newswire

play Anhören
share Teilen
feedback Feedback
copy Kopieren
newsletter
font_big Schrift vergrößern
Grail Inc 100,98 $ Grail Inc Chart -3,56%
Zugehörige Wertpapiere:

Analyst Day 2025 Webcast to Begin at 11:00 a.m. ET on November 13th

MENLO PARK, Calif., Oct. 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2025 following the close of market on Wednesday, Nov. 12, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.

Third Quarter 2025 Webcast and Conference Call Details
A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com.  

Please register for the live event at https://grail-q3-financial-results-2025.open-exchange.net/registration.

To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.

GRAIL Analyst Day 2025
Additionally, GRAIL will host its Analyst Day 2025 the following day, Tuesday, Nov. 13, 2025, at GRAIL's central laboratories in Research Triangle Park, North Carolina beginning at 11:00 a.m. ET.

The live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com and at https://grail-analyst-day-2025.open-exchange.net/registration.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-third-quarter-2025-financial-results-302598777.html

SOURCE GRAIL, Inc.


Für dich aus unserer Redaktion zusammengestellt

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Weitere Artikel des Autors

Themen im Trend